Serological Markers of Hepatitis Viruses in Patients and Contacts from a Low Prevalence Population in South Hungary in 1994–2001

Ildikó Seress
1†, Younes Ali Saleh2, Judit Brojnás2, György Berencsi2, and László Nagymajtényi1

1 Department of Public Health, University of Szeged, Szeged, Hungary
2 Division of Virology, Béla Johan National Center of Epidemiology, Budapest, Hungary

Deceased on 6 August, 2001.
Corresponding author: László Nagymajtényi
    Department of Public Health
    University of Szeged
    Dóm tér 10
    H-6723 Szeged, Hungary
    Telephone: +36-62-545-119
    Fax number: +36-62-545-120
    E-mail: nml@puhe.szote.u-szeged.hu

CEJOEM 2003, Vol.9. No.4.: 243–252


Key words:
Hepatitis A virus, hepatitis B virus, hepatitis C virus, multiple infections


Abstract:
Between 1994 and 2001, more than 30,000 hepatitis virus marker-specific serological tests were performed. Samples were taken from 17,994 persons suffering from hepatic disorders, and/or from their family members, with the aim of detecting hepatitis virus markers in the population of South Hungary. Hepatitis A virus (HAV)-specific antibodies, hepatitis C virus (HCV)-specific antibodies, hepatitis B virus (HBV) surface antigen (HBsAg) were tested using commercial ELISA reagents. The age of the persons was recorded at the time of blood sampling. In case the possibility of an acute or chronic viral hepatitis was diagnosed, further samples were taken from the patients and their family members were also sampled. The total number of persons of known age and residence with serological markers was 1193 (6.6% of the total population studied). Of these, 66 (6.4%) had acute epidemic hepatitis A infection. The number of persons with acute HBV infection or HBV carrier state was 263 (21.8%), and 244 (20.6%) persons were found hepatitis C-positive. Multiple infections (20 of 1193) were also identified. Five patients had acute HAV infection and probably chronic HCV disease, four had HBV carrier state and acute HAV infection. In 3 patients, acute HAV infection was combined with chronic carrier state of both HBV and HCV. Chronic carrier state of HBV and HCV was supposed in 6 persons. Two persons had Helicobacter pylori seropositivity complicating acute hepatitis. The etiology of 107 illnesses remained unclear. Introduction of hepatitis E and G reagents might reveal the etiology of these and other cases, too.
    The findings indicate that HBV or HCV carrier persons are at high risk of HAV infections. The data confirm previous suggestions that septic infection with Mycoplasma pneumoniae may cause acute hepatic disorders in the absence of both lung involvement and hepatitis virus markers. The main practical suggestion from this work is to use active immunisation of all persons suffering from chronic HCV disease with both HAV and HBV vaccines (or HAV only if HBV carrier state was verified).


Received: 5 January 2004
Accepted: 17 February 2004

| Back |